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The factors determining the course of glomerular fitration
rate (GFR) and albumin excretion rate (AER) and the
expression of mRNA of slit diaphragm (SD) and podocyte
proteins in microalbuminuric, hypertensive type II diabetic
patients are not fully understood. GFR, AER, and SD protein
mRNA were studied in 86 microalbuminuric, hypertensive,
type II diabetics at baseline and after 4-year random
double-blind treatment either with 40 mg simvastatin
(Group 1) or with 30 g cholestyramine (Group 2) per day.
Both groups had at baseline a GFR decay per year in the
previous 2–4 years of 3 ml/min/1.73 m2. Both Groups 1 and
2 showed a significant decrease of low-density lipoprotein
cholesterol levels after simvastatin and cholestyramine
treatment (Po0.01). No change from base line values was
observed as for hs-C-reactive protein and interleukin-6. A
significant decrease of 8-hydroxydeoxyguanosine urinary
excretion was observed after simvastatin treatment. GFR
did not change from baseline with simvstatin, whereas a
decrease was observed with cholestyramine treatment
(simvastatin vs cholestyramine: 0.21 vs –2.75 ml/min/
1.73 m2, Po0.01). AER decreased in Group 1 (Po0.01), but
not in Group 2 patients. Real-time polymerase chain reaction
measurement of mRNA SD proteins (CD2AP, FAT, Actn 4,
NPHS1, and NPHS2) significantly increased in kidney biopsy
specimens after simvastatin, but not cholestyramine
treatment. Simvastatin, but not cholestyramine, 4-year
treatment maintains steady patterns of GFR, and improves
AER and expression of SD proteins in type II diabetes,
despite similar hypocholesterolemic effects in circulation.
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It has been shown that the course of renal function is ominous
in some type II diabetic patients, who have been called
‘progressors,’ whereas other patients show steady patterns of
renal function for years (‘non-progressors’).1–4 Similar findings
have been reported also in type 1 diabetic patients.5 Prolonged
hyperglycemia causes chronic complications of diabetes.6 Tight
blood pressure control delays the progression of renal damage
in diabetic patients with nephropathy.7–10 Neverthereless, still
15–20% of the diabetic patients relentlessly develop end-stage
renal disease, despite aggressive antihypertensive therapy.
Tonolo et al.11,12 demonstrated that statins decrease the
rate of albumin excretion rate (AER) in type II diabetics with
microalbuminuria. This latter improvement of the course of
renal function has been confirmed by a metanalysis of reports
in literature by Fried et al.13 Van Wijk et al.14 reported that
an increase of simvastatin treatment from 20 to 80 mg/day
improved chylomicron remnant clearance in comparison
with the lower 20 mg/day dose. Furthermore, the effects of
statins are not merely related to their hypocholesterolemic
effects.15 Therefore, we decided to use a higher simvastatin
dose in the present paper, that is 40 mg/day.
We identified a subgroup of 86 consecutive, newly recrui-
ted, type II diabetic patients, who had these clinical charac-
teristics: a rapid deterioration of glomerular fitration rate
(GFR) (progressors), hemoglobin A1c 47%, and prolifera-
tive or background diabetic retinopathy.4,16
Our aim was to investigate the effects of simvastatin and
cholestyramine treatment on the course of renal function, in
type II diabetic ‘progressor’ patients.
RESULTS
The two groups showed similar demographic characteristics
at baseline, before treatment either with simvastatin (range
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3.7–4.2 years) or with cholestyramine (range 3.8–4.2 years)
(Tables 1 and 2). The two groups of patients had similar
histologic renal patterns at baseline (Figures 1 and 2, panels
1–12). Some change of the patterns of renal lesions in the
kidney specimen was observed both after simvastatin and after
cholestyramine treatment. For instance Figure 1 shows that
an increase of arteriolar hyalinosis was observed in a patient
with mild glomerular lesions at baseline after simvastatin
treatment (panel 1 vs 2). On the contrary, a slight decrease
of mesangial expansion was observed in a Category 2 patient
after simvastatin treatment (panel 3 vs 4) (Figure 1). Figure 1
also shows a further deterioration of renal lesions in Category
3 patients after simvastatin treatment. Figure 2 shows an
increase of mesangial expansion in a Category 1 patient after
cholestyramine treatment (panel 7 vs 8). With regard to
another patient in Category 2, the extent of mesangial expan-
sion was similar at baseline and after cholestyramine
treatment, even if also in this patient arteriolar hyalinosis
appeared more severe after cholestyramine treatment. Even-
tually, Figure 2 shows that the patterns of interstitial lesions
were more severe in a Category 3 patient after cholestyramine
treatment. To accomplish a broader and more complete
evaluation of the paterns of the histologic lesions at renal
level, we also evaluated three numerical parameters using light
microscopy (see Materials and Methods). A slightly significant
improvement was observed after simvastatin, but not after
cholestyramine treatment (Table 6). Glycemic control was
satisfactory, having achieved an average value of 7.4 or 7.3%
of hemoglobin A1c throughout the follow-up period (Table 2),
as compared with previous studies from our clinical center,
during which average hemoglobin A1c blood concentrations
were always higher than 8.0%. Blood pressure control was also
tight, showing average levels of systolic and diastolic blood
pressure below 140/90 mm Hg, even if not below 130 mm Hg
as for systolic levels (Table 2). Both simvastatin and
cholestyramine treatment significantly decreased lipid levels
to similar patterns (Table 3). On the contrary, no significant
changes were observed during both treatments as regards
hs-C-reactive protein levels (Table 3). Serum interleukin-6
levels were similar in Groups 1 and 2 patients at baseline
(5.970.4 vs 6.170.5 pg/ml, NS) and no significant change
from baseline was observed after both treatments. The mean
urinary excretion of 8-hydroxydeoxyguanosine (8-OH-dG)
(mg/g creatinine) was similar in the 43 simvastatin treated and
43 cholestyramine treated at baseline (Table 4, data regarding
42 and 40 patients, respectively, are shown). Simvastatin
Table 1 | GFR and AER (in triplicate) evaluation
Recruitment Randomisation and follow-up Washout 
ACE + Atenolol + thiazides ACE + Atenolol + thiazides No treatment
SimvastatinMetformin with or without insulin 
No thiazides
No atenolol
No ACE
Ca2+ Channel Blockers
(if needed) 
Cholestyramine
No simvastatin 
No cholestyramine 
Metformin with or without insulin Metformin and insulin
0 3 0 2 4 
years
2 1 (15 days) (15 days)
 Washout 
Cholestyramine
Simvastatin
ACE, angiotensinsin-converting enzyme inhibitors; AER, albumin excretion rate; GFR, glomerular fitration rate.
The flow chart which describes the drug treatment of 86 consecutive, hypertensive type 2 microalbuminuric patients before the recruitment, during the hypoglycemic and
antihypertensive, and hypocholesterolemic treatment and at the end of the follow-up period. Four patients were excluded before the first control at the 6th month. All the
other patients were recruited as consecutive patients, if they had a GFR decay 43 ml/min/year/1.73 m2 in the preceding 3 years. The statistician of the Department of Clinica
Medica of the University of Sassari allocated blindly the patients to simvastatin or to cholestyramine treatment on the basis of the intention to treat principle. Each arrow on
the top represents the control of GFR and AER (in triplicate as for AER).
Table 2 | Mean7s.e. age, duration of the disease, HbAlc, and BP
Age (years)
Duration of the
disease (years) HbAlc %
Systolic BP
(mm Hg)
Diastolic BP
(mm Hg)
Microalbuminuric Type 2
diabetics Group 1 (n=42)
6278 1374 7.470.7 132714 7774
Microalbuminuric Type 2
diabetics Group 2 (n=40)
6174 1274 7.370.6 130713 7574
BP: blood pressure; HbA1c: hemoglobin Alc.
Mean7s.e. clinical features of 82 (statistical comparison have been performed taking into consideration all the 86 patients) diabetic patients at baseline (age, duration) and
after 4 year therapy with 40 mg per day of simvastatin or with 30 g per day of cholestyramine simvastatin (HbAlc and BP).
Group 1: simvastatin-treated patients.
Group 2: cholestyramine-treated patients.
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tretment, but not cholestyramuine treatment, decreased the
urinary excretion of 8-OH-dG (Table 4).
Body mass index was 2770.4 and 2870.6 kg/m2 at base-
line in Groups 1 and 2, respectively, and no significant change
from baseline was observed after both treatments. GFR did not
change from baseline at the end of the 4-year treatment with
simvastatin (Table 5). On the contrary, a significant decrease
of GFR was observed in the cohort of patients treated with
cholestyramine (cholestyramine vs simvastatin: 2.75 ml/
min/1.73 m2 per year vs 0.21 ml/min/1.73 m2 per year,
Po0.01). However, also cholestyramine treatment slightly
blunted the decay of GFR, as the average GFR decrease per
year in the overall group of patients before entering the
present study was 3.9 ml/min/1.73 m2/year. AER signi-
ficantly decreased in the patients treated with simvastatin,
but not in those treated with cholestyramine (Table 5). The
percentage of patients who had steady normoalbuminuria,
during the 4th year of follow-up instead of microalbuminuria,
was three-fold higher during simvastatin than during
cholestyramine treatment (29 vs 8%, Po0.01). Overt protein-
uria did develop in 15% of cholestyramine-treated patients
and in 4% of simvastatin-treated patients (Po0.01).
Glomeruli from type II diabetic patients were always
positive for ox-low-density lipoprotein (ox-LDL), with a
variable intensity and pattern of deposition (Figures 4–5). No
deposition of ox-LDL was ever observed in the glomeruli of
the five non-diabetic, control hypertensive subjects (Figure 6).
We described such latter observation in two different ways:
(1) in a qualitative and quantitative fashion (Figures 4, 5, and
7, Table 6). More particularly as regards the quantitative
fashion the deposition of ox-LDL was expressed as % of
fluorescence staining for each glomerular area. These data
(ranging from 10–20% to 60–80%) were represented in
relationship with NPHS1 mRNA normalized for the amount
of extracted RNA (Figure 7). At baseline both (15 simvastatin-
and 15 cholestyramine-treated patients) had a deposition of
ox-LDL broadly dispersed in a wide range, always associated
with markedly low NPHS1 patterns (Figure 7). Only
simvastatin treatment resulted in a significant decrease of
the deposition of ox-LDL and in a significant increase of
NPHS1 patterns (Figure 7). The deposition of ox-LDL was
similar in patients in Categories 1–3 according to the
histologic classification we have previously described. Table 7
shows the means7s.d. of some slit diaphragm (SD) mRNA
expression in specimens from kidney biopsy of Groups 1 and
2 patients at baseline and after simvastatin and cholestyr-
amine treatment. CD2AP, FAT, Actn4, NPHS1, and NPHS2
mRNA expressions reported as percentage of the internal
standard mRNA 18S were all significantly higher in the
simvastatin-treated patients, in comparison with both base-
line values in the simvastatin Group 1, and baseline and
4-year values after follow-up in the cholestyramine cohort.
No change was observed after cholestyramine treatment.
DISCUSSION
The results of the present study demonstrate that both
simvastatin and cholestyramine reduce circulating LDL levels
in microalbuminuric, type II diabetic, hypertensive patients,
but that only simvastatin abates progression of renal damage.
Moreover, our results show that simvastatin markedly
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Figure 1 | Patterns of the glomerular and renal lesions in kidney
specimens from Categories 1–3 patients at baseline (panels 1, 3,
and 5) and after simvastatin treatment (panels 2, 4, and 6).
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Figure 2 | Patterns of the glomerular and renal lesions in kidney
specimens from Categories 1–3 patients at baseline (panels 7,
9, and 11 ) and after cholestyramine treatment (panels 8, 9,
and 12).
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improves mRNA expression of SD proteins. It does not
appear from our data that either simvastatin or cholestyr-
amine treatment modifies hs-C-reactive protein- and inter-
leukin-6-circulating levels. Eventually the amelioration of
AER and expression of mRNA of SD proteins, as well as the
stabilization of GFR patterns, were associated with decrease
of 8-OH-dG urinary excretion.
Our findings suggest that statins increase the expression of
nephrin, podocin, CD2AP, and FAT, alpha-actin proteins.
These proteins are tightly associated and are embedded into
lipid rafts.17–21 The response of SD proteins to exogenous
signals is orchestrated by a number of molecules that cluster
in cholesterol-rich areas of the cell, the lipid rafts. Several
evidences suggest that the inhibition of cholesterol synthesis
by statins modifies these lipid rafts.17–21 With regard to our
findings on reactive oxygen species, it has to be pointed
out that reactive oxygen species lead to oxidative damage of
DNA, aging, and degenerating disease. 8-OH-dG was first
reported as causing oxidative DNA damage.22–25
The mechanisms underlying the relationship between
the decrease of 8-OH-dG and the amelioration of renal
function could be due to a decreased overproduction of
reactive oxygen species.26 This latter hypothesis is suggested
by the observation from other research groups17-19,27,28 that
SD structure is rescued by oxygen radical scavengers. The
Table 5 | Mean7s.e. and median with ranges of GFR and AER
at baseline and after 4 years treatment with simvastatin and
cholestyramine
GFR (ml/min/1.73m2) AER (lg/mg) Normo Prot.
Simvastatin
B 9178 77 (31–259) — —
4 years 9077 40* (10–319) 29% 4%
Cholestyramine
B 9077 88 (34–261) — —
4 years 7978*,** 81 (17–399) 8%** 15%**
AER: albumin excretion rate; GFR: glomerular fitration rate.
Group 1: Simvastatin treated patients.
Group 2: cholestyramine-treated patients.
*Po0.05 baseline vs 4th year. **Po0.01 baseline vs 4th year.
NS=not significant baseline vs 4th year.
Mean7s.e. and Median with ranges of GFR and AER at baseline and after 4 year
treatment with simvasatatin and cholestyrramine. Precentage of patients showing
regression to normoalbuminuria (normo) and progression to proteinuria (prot).
NO oxidized 
LDL
With oxidized
LDL
200 kDa
300 kDa
Figure 3 | LDLs were purchased from Sigma. Before oxidation,
LDLs were dialyzed against sterile PBS at 41C for 2 h. The
oxidation was performed by incubating LDL solution with 10 mmol/l
CuSO4 at 371C for 24 h. Western blot analysis demonstrates the
specificity of the antibody against oxidized LDL.
Table 4 | Mean7s.e. urinary 8-OH-dG levels (lg/g creatinine)
in type 2 hypertensive microalbuminuric diabetic patients
(82) at baseline, and in 42 after 4-year simvastatin and in
40 after 4-year cholestyramine treatment
Baseline 4th year
Simvastatin 4.4570.15 3.2070.20**
Cholestyramine 4.4970.11 3.9170.14NS
8-OH-dG: 8-hydroxydeoxyguanosine.
Group 1: Simvastatin treated patients.
Group 2: Cholestyramine treated patients.
**Po0.01 baseline vs 4th year.
NS=not significant baseline vs 4th year.
Table 3 | Mean7s.e. and geometric mean with range serum and plasma levels of CH, TG, LDL cholesterol, HDL cholesterol, and
highly sensitive C-protein-reactive protein (hsCRP) at baseline (B) and after 4 years of simvastatin or cholestyramine treatment
CH (mg/dl) TG (mg/dl) LDL (mg/dl) HDL (mg/dl) HsCRP (mg/l)
Simvastatin
B 231712 191745 150713 4375 2.25 (0.7-2.99)
4 years 170713* 148739* 99715* 4276 2.19 (0.8-2.81)
Cholestyramine
B 227716 188750 148716 4477 2.11 (0.7-2.70)
4 years 166718* 146748* 97718* 4578 2.13 (0.6-2.90)
CH: total cholesterol; HDL: high-density lipoprotein; hsCRP: highly sensitive C-protein-reactive protein; LDL: low-density lipoprotein; TG: triglycerides.
Mean7s.e. lipid patterns and hsPCR values of 82 diabetic patients at baseline and after 4-year therapy with 40 mg per day of simvastatin or with 30 g per day of
cholestyramine simvastatin (statistical comparison have been performed taking into consideration all the 86 patients).
Group 1: simvastatin-treated patients.
Group 2: cholestyramine-treated patients.
*Po0.01, baseline vs 4th year.
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decrease of ox-LDL and the pleiotrophic effects secondary to
simvastatin administration, at glomerular level, might play a
role from this point of view.21 Eventually, the protective effect
of statins at glomerular level is not associated with significant
changes of the circulating levels of hs-C-reactive protein and
interleukin-6. These latter finding do not support the tenet
that a modulation of the systemic immunologic action is the
most important mechanism accounting for the benefits of
simvastatin at renal level.
Whatever the mechanism, which explains the improve-
ment or the maintaining at steady levels of several parameters
of renal function after simvastatin, we believe that the present
study may be useful to prevent end-stage renal disease in type
II diabetes.
MATERIALS AND METHODS
Subjects and methods
Table 1 describes the procedures we followed to recruit type II
diabetics with hypertension (4130/85 mm Hg), and microalbumin-
uria, treated by angiotensinsin-converting enzyme inhibitors
(5 mg ramipril or 20 mg lisinopril/day), 12.5 mg/day thiazides, and
100 mg/day atenolol in the last 3 years, with a glycemic control
accomplished by 1500 mg/day metformin with either three insulin
analogs before meals or once daily long-acting insulin injection. The
definition of microalbuminuria was a median between 30 and
300 mg/mg of albumin/creatinine, in three consecutive urine speci-
mens (Tables 1 and 2).29 The main criterion for the inclusion into
the study was that a decrease of GFR41 ml/min/1.73m2/year had to
be observed during the 3 years before the recruitment. The rationale
is that a decrease of 1 ml/year is usually observed in all Caucasian
subjects older than 50 years.30 We evaluated GFR from the clearance
rate of 51Cr-ethylenediamine tetraacetic acid technique.16,31 GFR
course was evaluated using a permutation approach to a Hotelling’s
T(2) statistic.32 A list of 86 consecutive patients who had a GFR
decline during the last 3 years of follow-up (see Table 5) 43 ml/
min/1.73 m2/year were randomly allotted, either to 40 mg/day
simvastatin or to 30 g/day cholestyramine treatment. The analysis
of the results was carried out on the basis of the intention to treat
principle. All the 86 patients were included in the statistical analysis
on the basis of the intention to treat principle. In the Result and
Cu2+ox-LDL Cu2+ox-LDL Cu2+ox-LDL
Cu2+ox-LDL Cu2+ox-LDL Cu2+ox-LDL
NPHS1NPHS1 NPHS1
NPHS1NPHS1 NPHS1
a b c
d e f
Figure 4 | Qualitative expression of the fluorescence patterns of ox-LDL and NPHS1 at glomerular level. From three out of 15 type II
diabetic, hypertensive, microalbuminuric patients, at (a–c) baseline and (d–f) after 4-year therapy with 40 mg per day of simvastatin. These
images are typical examples of three patients ((a) 1st patient, (b) 2nd patient, (c) 3rd patient at baseline, and (d–f) after treatment) out
of 15 similar analyses carried out in 15 patients before and after treatment with simvastatin treatment.
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Table sections we showed the data of 82 patients at baseline. Two
patients developed renal cancer. One patient developed myocardial
infarction. One patient showed a 3- to 4-fold increase of
transaminases above baseline levels during the first 5 months after
recruitment. Forty-two patients on simvastatin and 40 on
cholestyramine ended the study without clinical side effects
(Table 1). Thirty patients out of the above-mentioned two groups
of patients were studied as for ox-LDL after random selection (first
one yes, the second one no, the third one yes, etc.) after casual
mixing of the entire series of patients till the number of 15 was
reached in each of the two groups of simvastatin- and cholestyr-
amine-treated patients. Plasma triglycerides were measured as
glycerol by colorimetric method after enzymatic hydrolysis. High-
density lipoprotein cholesterol levels were measured enzymatically
after precipitation of very low-density lipoprotein, intermediate-
density-lipoprotein, and LDL from plasma. LDL cholesterol was
measured using the formula LDL cholesterol¼ total cholesterol
high-density lipoprotein cholesteroltriglycerides/5.33 Measure-
ment of highly specific hs-C-reactive protein levels was obtained
by nephelometry with a highly sensitive immunoassay that used a
monoclonal antibody coated to polystrene particles (hs-C-reactive
protein). The interassay coefficient of variation for the CRP
measurement was 4%.34 Fasted serum levels of interleukin-6 were
determined by enzyme-linked immunosorbent assay (Quantitative
IL-6; R&D Systems, Oxford, UK).35 The sensitivity of the assay was
0.70 pg/ml.
Human biopsies
Light microscopy. Kidney biopsies were performed under
ultrasound guidance. After kidney biopsy, tissue was immediately
examined under a dissecting microscope to ensure adequate
numbers of glomeruli. Most of the core was placed in Zenker’
fixative, embedded in paraffin, and processed for light microscopy.
Light microscopy sections (2mm thick) were stained with hematoxy-
lin and eosin and periodic acid Shiff. The following classification
was adopted: Category 1, normal or near normal renal structure.
These patients had biopsies that were normal or showed very
mild mesangial expansion, tubulointerstitial changes, or arteriolar
hyalinosis in any combination (Figures 1 and 2, panels 1 and 2 and
panels 7 and 8). Category 2, typical diabetic nephropathy—these
patients had biopsies that were balanced severity of glomerular,
Cu2+ox-LDL Cu2+ox-LDL Cu2+ox-LDL
Cu2+ox-LDL Cu2+ox-LDL Cu2+ox-LDL
NPHS1NPHS1 NPHS1
NPHS1NPHS1 NPHS1
g h i
l m n
Figure 5 | Qualitative expression of the fluorescence patterns of ox-LDL and NPHS1 at glomerular level from three out of 15
type II diabetic patients, at (g–i) baseline and (l–n) after 4-year therapy with 30 g per day of cholestyramine. These images are typical
examples of three patients ((g): 1st patient, (h) 2nd patient, (i) 3rd patient at baseline, and (l–n) after treatment) out of 15 similar analyses
carried out in 15 patients before and after treatment 30 g per day of cholestyramine.
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severe not mild mesangial expansion, tubulointerstitial changes, or
arteriolar hyalinosis changes. This picture is typical of that seen in
Type I diabetes with peculiar diabetic nephropathy changes (Figures
1 and 2, panels 3 and 4 and panels 9 and 10). More details have been
provided further on in the text. Category 3, atypical patterns of renal
injury—these patients had absent or only mild glomerular diabetic
changes with severe renal structural lesions, including the following:
(a) tubular atrophy, tubular basement membrane thickening and
reduplication and interstitial fibrosis; (b) advanced glomerular
arteriolar hyalinosis commonly associated with atherosclerosis of
large vessels; (c) global glomerular sclerosis (425%) in the presence
or absence of mild mesangial expansion, (see later on in the details
for this classification (Figure 1 and 2, panels 5 and 6; panels 11 and
12). Other details have been described elsewhere.4,16,36,37 The index
of mesangial expansion (IME) was determined by a semiquantitative
estimate of the width of mesangial zones in each glomerulus. 0 was
used as normal, 1.0 as twice normal thickness, 2.0 as three times
normal thickness, etc. The mean of the grades for each glomerulus
for IME was determined for each patient and represents the IME
score reported in the current study (Table 6). The mean difference
between two readings was 10.5%, with mean differences in IME
index of 0.10. The index of interstitial fibrosis was determined
as a semiquantitative estimate of the space occupied by fibrous
tissue separating cortical tubules; further details are given in.36
The index of arteriolar hyalinosis was determined as a semiquanti-
tative estimate of replacement of arteriolar smooth muscle by
periodic acid Shiff-positive materials.36 Patients in Category 1 were
four in number. Patients in Category 2 were 56 patients with
typical diabetic nephropathology (30 in the simvastatin group
and 26 in cholestyramine group). Patients in Category 3 were
22 patients who had atypical patterns of renal injury as described
before (10 in the simvastatin group and 12 in the cholestyramine
group).4,16,37
Evaluation of NEPSH1 and other podocyte and SD proteins
Sequences specific for intracellular (amino acid (aa) 101–1126:
TEAGSEEDRV RNEYEESQT GERDQ) and extracellular (aa 1039–
1056: HQ PSGEPDQLPTEPPSG) oligopeptides were selected over
Cu2+ox-LDL Cu2+ox-LDL
NPHS1 NPHS1
Control Control
Figure 6 | Qualitative expression of the fluorescence patterns of
ox-LDL and NPHS1 in a glomerulus from one control subject out
of the five controls, (details in the text), with hypertension at
baseline.
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Figure 7 | Quantitative reverse transcriptase-PCR analysis of
NPHS1 normalized for mRNA content in relationship with the
quantitative evaluation of fluorescence staning of ox-LDL in the
30 diabetic patients before and after simvastatin (15 patients)
and cholestyramine (15 patients) treatment (see details in the
text for the recruitment and blind evaluation of this cohort of
patients from the overall 86 patients). This approach was not
applied in Table 7, which reported quantitative reverse
transcriptase-PCR analysis of the other SD proteins calculated in
the same fashion used for NPHS1 in Figure 7, after correction for
the internal standard without further correction for RNA content,
which was considered interesting, even if not needed, for the
comparison with the glomerular content of ox-LDL. Closed circles
represent patients at baseline before simvastatin. Squares represent
patients after simvastatin. Rhombs represent patients at
baseline before cholestyramine. Triangles represent patients
after cholestyramine.
Table 6 | Mean7s.e. morphologic findings in 82 type 2
diabetic patients treated either with simvastatin or with
cholestyramine at baseline and after 4 year follow-up
Index of
mesangial
expansion
Index of
interstitial
thickness
Index of
arteriolar
hyalinosis
Simvastatin
B 0.6170.13 0.3870.09 0.6570.17
4 years 0.4770.09* 0.3070.17NS 0.4470.11*
Cholestyramine
B 0.6070.15 0.4070.10 0.6770.15
4 years 0.5970.13NS 0.3870.13NS 0.5870.16NS
Group 1: simvastatin-treated patients.
Group 2: Cholestyramine-treated patients.
*Po0.05 baseline vs 4th year.
NS=not significant baseline vs 4th year.
Means7s.e. of the numerical parameters using light microscopy to calculate the
percent global glomerular sclerosis, the index of mesangial expansion and that of
interstitial thickness in specimens from kidney biopsies in Groups 1 and 2 82
diabetic patients at baseline and after 4-year therapy with 40 mg per day of
simvastatin or with 30 g per day of cholestyramine simvastatin.
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the human nephrin sequence (Gene Bank, AF035835) using the
PredictProtein program via internet at the European Molecular
biology Laboratory network available in the University of Sassari. A
similar approach was followed as regards CDA2, Actn4, FAT, and
NEPHS2 proteins. These peptides showed no homology to other
known protein sequences and were synthesized and purified. The
proteins were run through reducing 10% polyacrilamide gel in the
Protean Mini-gel electrophoresis system (BioRad Laboratories) and
then transferred to nitrocellulose filters (Amersham, Biosciences,
Milan, Italy). After blocking for 2 h at room temperature with 3%
non-fat-dried milk (Valio, Helsinki, Finland) in phosphate-buffered
saline (PBS), the filters were incubated with antibodies Aff 338 (1:5)
and Aff 380 (1:5) in PBS containing 1% non-fat-dried milk and
0.002% sodium azide for 1 h at room temperature. The filters were
then washed several times in PBS containing 0.2% Tween 20, further
incubating with peroxidase-conjugated, affinity-purified goat anti-
rabbit immunoglobulin G antibody (Jackson Immunoresearch Lab,
West Grove, PA, USA, dilution 1:40) for 1 h at room temperature
and washed as above. The bound antibodies were detected with
Super Signal enhanced chemiluminiscence substrate (Pierce Rock-
ford, IL, USA). The Aff 338 and Aff 380 rabbit polyclonal antibodies
were originally raised against the major splicing variant designated
as nephrin alpha, using a recombinant fusion protein alpha 435 as
the antigen as described before in the text. Raising polyclonal
antibodies against CDA2, Actn4, FAT, and NEPHS2 were accomp-
lished using the extracellular segments of several human podocyte
proteins analyzed by hydrophobicity plots using Kyte–Doolittle
curves and the scale website. The most hydrophilic portions specific
to the protein were selected for peptide synthesis, also using the
PredictProtein program via internet. Peptide sequences that were
chosen were homologous (maximum of one aa difference) with the
corresponding human sequences. Before immunization, 15 ml of
preimmune serum was obtained from each rabbit. Two peptides (of
15 aa each) for each protein were used to immunize two rabbits each
to raise polyclonal antibodies. The initial immunization was carried
out with complete Freund’s adjuvant, whereas boosters at days 20,
40, and 60 were given with incomplete Freund’s adjuvant. Enzyme-
linked immunosorbent assay titers for antigen-specific reactivity
were checked after the first bleed, at day 70, using peptide-coated
wells. The following antibodies were raised: anti-human antibodies
CD2AP, anti-FAT, anti-Actn4, and anti-NPPHS2 (dilution 1:20).
Secondary antibodies for immunofluorescence were purchased from
Sigma-Aldrich (St Louis, MO, USA).
Immunofluorescence microscopy
Immunofluorescence staininig was performed on 4 mm frozen
sections and on semithin frozen sections from kidney specimens.
After rinsing with PBS, uspecified binding sites were blocked with
2% fetal calf serum, 2% bovine serum albumin and 0.2% fish gelatin
in PBS for at least 30 min. Primary antibodies (prediluited in
blocking solution) were applied for 60 min at room temperature.
Antigen–antibody complexes were visualized using fluorochrome
(Cy2 or Cy3)-conjugated secondary antibodies (Biotrand, Cologne,
Germany) prediluited in blocking solutions. Sections were washed
with PBS, rinsed with H2O, and mounted in 15% mowiol
(Calbiochem, Bad Sodem, Germany) and 50% glycerol PBS. After
overnight drying, specimens were analyzed and documented with
Polyvar 2 photomicroscope (Leica, Bensheim, Germany). Simulta-
neous confocal double fluorescence microscopy was carried out with
Zeiss 410 ultraviolet laser scanning microscope (Carl Zeiss,
Obertochen, Germany) equipped with appropiate filters. Micro-
graphs were taken using an imaging recorder (Focus Graphics,
Foster City, CA, USA) and digitally processed using the Adobe,
Phosop 4.0 program. These procedures were basically based on the
study of Mundel et al.38 with the necessary modifications.
Ox-LDL preparation and evaluation
Before oxidation, LDL solution at the concentration of 1 mg/ml was
dialyzed against sterile PBS at 41C for 2 h. The oxidation was
performed by incubating LDL solution with 10mmol/l CuSO4 at
371C for 24 h, according to Jialal et al.39 (Figure 3). In order to check
the specificity of the antibody against ox-LDL used in this study,
native LDL and Cu2þ ox-LDL (10 mg) were run on a 5% sodium
dodecyl sulfate polyacrylamide electrophoresis gel and transferred to
a nitrocellulose membrane by electroblocking. Membranes were then
incubated with primary rabbit anti-Cu2þ LDL antibody39 followed
by secondary antibody. Positive reaction products were identified by
enhanced chemiluminiscence (ECL, Amersham) and autoradio-
graphy. Negative controls were performed concurrently by loading
buffer instead of proteins on sodium dodecyl sulfate polyacrylamide
electrophoresis gel or by substituting buffer (Figure 3).
mRNA renal expression of podocyte and SD proteins in
kidney specimens
mRNA has been extracted from kidney biopsies using the
guanidinium thiocyanate phenol–chloroform method with RNA
STAT-60. RNA quality and quantity was controlled by microfluid
Table 7 | Mean7s.d. values of mRNA expression of slit-diaphragm proteins in specimens from kidney biopsy from
hypertensive, microalbuminuric type 2 diabetics expressed as % of each protein (CD2AP, FAT, Actn 4, NPHS1,
and NPHS2) of the 18S mRNA expression (internal control)
CD2AP FAT Actn 4 NPHS1 NPHS2
Simvastatin
B 0.04970.039 0.02470.010 0.01970.012 0.01270.010 0.02270.017
4 years 1.01170.042* 0.8870.15* 0.9770.16* 0.8570.22* 0.7570.19*
Cholestyramine
B 0.05570.041 0.02670.013 0.02370.014 0.01470.011 0.02570.018
4 years 0.06070.040 0.03070.011 0.02670.013 0.01970.014 0.03070.022
SD: slit diaphragm.
Means7s.d. of some SD mRNA expression in specimens from kidney biopsy in Groups 1 and 2 82 diabetic patients at baseline and after 4-year therapy (statistical comparison
have been performed taking into consideration all the 86 patients). Expressed as percent of each protein of the 18S mRNA expression (internal control) (statistical comparison
have been performed taking into consideration all the 86 patients).
Group 1: simvastatin-treated patients.
Group 2: cholestyramine-treated patients.
*Po0.01 baseline vs 4th year.
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electrophoresis using the RNA 6000 LabChip on a 2100 Bioanalyzer
(Agilent Technologies, Waldbronn, Germany) yielding 0.07–2.5mg of
total RNA. From the extracted RNA, single-strand cDNA was
obtained using a reverse transcriptase (Superscript II) and random
hexamer primers. We designed polymerase chain reaction amplifi-
cation primers and probes, for each gene, which have been analyzed
in an Applied Biosystem analyzer (ABI 7900, Roche, Milano, Italy)
in the presence of a standard, to calibrate the reactions. For nephrin,
primers were forward 50-CAGGAGCACGGCATCACA, reverse 50-
TGTTCTCAGTCTGGGATGCAT, and probe was 6FAM-TGCAGGT
CACCTTTCCCCCTAGTGC-MGBNFQ. For podocin primers were
forward 50- AATTATATTCCGACTGGGACATCTG, reverse 50-GCA
GGGCAAAAAAAAGAAAAGA, and probe was 6FAM-TTCCTGGA
AGAGCCAAAGGCCCTG-MGBNFQ. For the analysis of the
remaining genes (CD2AP, Actn4, and FAT), the following kits from
ABI (USA) were used: Hs00183713_m1-CD2AP, Hs00245168_m1-
ACTN4, Hs00170627_m1-FAT. The reverse transcriptase-PCR reac-
tion contained buffer, 200mM deoxyribonucleotide triphosphate,
5.5 mM MgCl2, 100 nM forward and reverse primers, 50 nM FAM
probe, 0.05 U/ml AmpliTaqGold, and 5ml cDNA. The thermocycler
protocol consisted of 40 cycles (150 at 951 and 10 at 601 each). Then,
18S RNA was choosen as internal standard. The internal standard
(18S) and the selected genes were analyzed for any single sample in
the same batch. All PCR products were confirmed to be the expected
cDNA by subcloning the PCR product using the PGEM-T vector
system (Promega, Milano, Italy) and then sequencing the cloned
fragments. For the selected genes (CD2AP, FAT, Actn4, NPHS1, and
NPHS2) we calculated their relative expression in comparison with
the internal standard (18S RNA) in each sample. After correction for
the 18S, the amount of mRNA was corrected in each single sample,
also in comparison with the expression of the same gene measured
in a pool of RNA obtained from five non-diabetic subjects (control)
undergoing surgical nephrectomy for renal cancer (biopsy obtained
from the opposite kidney pole during surgery). From the computer-
generated plot of amplification during the reverse transcriptase-PCR
reaction, a threshold line was arbitrarily drawn in a position where
in all samples both internal standard (18S) and the genes under
evaluation were in the exponential phase. This threshold line
identifies in the exponential part of the plot a cycle, which is a direct
function of the original amount of mRNA in the sample, called cycle
threshold (Ct). Correction for the internal standard and control
sample is carried out using the following formula: Ct geneCt
18S¼DCt then DCt sample  DCt control ¼DDCt . The relative
expression of the sample under analysis for each gene is finally
calculated as 2DDCt : Data on this methodology has been previously
presented.16 NPHS1 was also expressed after normalization for
extracted RNA to evaluate its relationship with oxidized LDL in 15
renal human biopsies in the group on simvastatin and in 15 renal
human biopsies in the group on cholestyramine and in five normal
controls (patients with hypertension who underwent surgical
removal of one kidney for cancer).16
Analysis of 8-OH-dG in human urine
Urinary 8-OH-dG levels were measured using the automated
coupled-column HPLC-ECD system according to the method of
Kasai.22,23 The 8-OH-dG used for standards was obtained from
Sigma (Milano, Italy). The reversed phase column (Capcell Pak C18,
5 mM, 4.6 250 mm2) used in HPLC-2 for analysis of the 8-OH-dG
fraction was purchased from Shiseido (Japan). HPLC grades of
methanol and acetonitrile were purchased from Wako Pure
Chemical Industries and the Kanto Chemical Co. (Milano, Italy).
Primary end point
We aimed to evaluate the number of patients with a decrease of
GFR43 ml/min/1.73m2/year, during a follow-up period of 4 years
(range 3.7–4.2) in two groups of patients treated either by
simvastatin (43 patients) or by cholestyramine (43 patients). The
study was approved by the Ethical Committee of the University of
Sassari.
Calculation of the size of the subjects to be studied in each
group
The calculation of the size of subjects was based on the following
formula:. Bilateral significativity 0.05 with a power of 80%, if we
assume a difference between the two groups of 0.251.24 If
z2alpha¼ 1.96, z2beta¼ 1.64, sigma¼ 3.5 (see24 as for the coefficient
of error for repeated GFR measurement), and delta¼ 4.25 we have
Number ¼ 2 Sigma
2
Tð z alpha=2 þ z betaÞ2
delta2
Thus, in each group we needed at least 35 subjects. However, we
studied 43 patients in each group, because we were not sure that all
the patients would have accepted the entire protocol.
Statistics
Data are reported as mean7s.e. or s.d. when normally distributed,
and as medians with ranges when the data were not normally
distributed. The unpaired and paired Student’s t-test for parametric
parameters, the Wilcoxon test for non-parametric parameters, and
the quadratic chi test for the comparison of the data expressed as
percentages were calculated using the software SPSS analysis
approach.24
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